A liver‐specific gene expression panel predicts the differentiation status of in vitro hepatocyte models

Alternative cell sources, such as three-dimensional organoids and induced pluripotent stem cell-derived cells, might provide a potentially effective approach for both drug development applications and clinical transplantation. For example, the development of cell sources for liver cell-based therapy has been increasingly needed, and liver transplantation is performed for the treatment for patients with severe end-stage liver disease. Differentiated liver cells and three-dimensional (3D) organoids are expected to provide new cell sources for tissue models and revolutionary clinical therapies. However, conventional experimental methods confirming the expression levels of liver-specific lineage markers cannot provide complete information regarding the differentiation status or degree of similarity between liver and differentiated cell sources. Therefore, in this study, to overcome several issues associated with the assessment of differentiated liver cells and organoids, we developed a LiGEP (Liver-Specific Gene Expression Panel) algorithm that presents the degree of liver similarity as a “percentage”. We demonstrated that the percentage calculated using the LiGEP algorithm was correlated with the developmental stages of in vivo liver tissues in mice, suggesting that LiGEP can correctly predict developmental stages. Moreover, 3D cultured HepaRG cells and human pluripotent stem cell (hPSC)-derived hepatocyte-like cells (HLCs) showed liver similarity scores of 59.14% and 32%, respectively, although general liver-specific markers were detected. Therefore, our study describes the first quantitative and predictive model for differentiated samples, particularly liver-specific cells or organoids, and this model can be further expanded to various tissue-specific organoids. Our LiGEP can provide useful information and insights regarding the differentiation status of in vitro liver models. This article is protected by copyright. All rights reserved.